Design of a pharmaceutical quality system (PQS): Unterschied zwischen den Versionen
| (3 dazwischenliegende Versionen desselben Benutzers werden nicht angezeigt) | |||
| Zeile 1: | Zeile 1: | ||
| − | For companies manufacturing medicinal products, the terms quality | + | For companies manufacturing medicinal products, the terms quality management system (QMS) and pharmaceutical quality system (PQS) can be used interchangeably. As medicinal cannabis is classified as an active pharmaceutical ingredient (API) or medicinal product in the EU and is subject to EU GMP guidelines, the alternative usage also applies here. However, unlike a general ISO 900x QMS, a PQS must meet enhanced GMP requirements. |
<big>''Tip! Use the term PQS consistently to avoid confusion with ISO quality man-agement systems used in other industries and often used by suppliers.''</big> | <big>''Tip! Use the term PQS consistently to avoid confusion with ISO quality man-agement systems used in other industries and often used by suppliers.''</big> | ||
| − | The documents, instructions and records of the PQS are used to control and verify the quality-related processes carried out during the production of | + | The documents, instructions and records of the PQS are used to control and verify the quality-related processes carried out during the production of medicinal cannabis, the active pharmaceutical ingredient (API) or the medicinal product, thus translating the relevant regulatory requirements into practical solutions. |
== Aims and basic principles of the PQS == | == Aims and basic principles of the PQS == | ||
| − | Any patient who is ill and takes a drug hopes that it will work and cure the | + | Any patient who is ill and takes a drug hopes that it will work and cure the disease or at least relieve the symptoms. However, the scandal in the USA in 1937 involving the preparation Elixir Sulfanilamide, which caused the deaths of 107 patients, and the Thalidomide disaster in Germany in the early 1960s made it clear that one thing is more important: medicinal products must be safe. Therefore, the primary objective of the pharmaceutical quality system (PQS) is patient safety. Chapter 1 of the EU GMP Guidelines (RegLink: Chapter 1, PQS) states that all holders of a Manufacturing Authorisation must ensure that the medicinal products manufactured are |
* are fit for their intended use, | * are fit for their intended use, | ||
* comply with the requirements of the Marketing Authorisation or Clinical Trial Authorisation, and | * comply with the requirements of the Marketing Authorisation or Clinical Trial Authorisation, and | ||
| Zeile 13: | Zeile 13: | ||
The last bullet point shows how important patient safety is to the authorities: safety always comes first, followed by the quality and efficacy of the medicinal product. | The last bullet point shows how important patient safety is to the authorities: safety always comes first, followed by the quality and efficacy of the medicinal product. | ||
| − | The fact that medicinal cannabis in its various forms of administration is | + | The fact that medicinal cannabis in its various forms of administration is classified as a medicinal product in Europe means that this also applies to the production and marketing of medicinal cannabis. |
| − | Several stakeholders with different roles are working together to achieve this goal: the growers and manufacturers of medicinal cannabis flowers and | + | Several stakeholders with different roles are working together to achieve this goal: the growers and manufacturers of medicinal cannabis flowers and extracts, the wholesalers and the supervisory authorities. |
If medicinal cannabis is used as an active ingredient in the manufacture of a medicine, the manufacturer of the medicine must apply for an EU marketing authorisation. This process is not covered by this knowledge portal. | If medicinal cannabis is used as an active ingredient in the manufacture of a medicine, the manufacturer of the medicine must apply for an EU marketing authorisation. This process is not covered by this knowledge portal. | ||
| − | Only products that meet the defined requirements can be placed on the | + | Only products that meet the defined requirements can be placed on the market. The supervisory authorities carry out regular inspections of all manufac-urers of medicinal products to check their compliance with regulatory and pharmacopoeial requirements, including GMP and GDP. For this reason, European regulators also inspect the entire production chain of cannabis products worldwide. |
| − | The pharmaceutical manufacturer is obliged to implement, maintain and | + | The pharmaceutical manufacturer is obliged to implement, maintain and continuously improve a PQS (Pharmaceutical Quality System) to produce medicinal products that always meet the requirements. The PQS must be fully documented by means of instructions and records and must cover all aspects that individually or collectively affect the quality (and also safety and efficacy) of the medicinal product as specified in the pharmacopoeias. The PQS covers the entire lifecycle of the medicinal product from pharmaceutical development through technology transfer to commercial production until the product is discontinued. It also includes the development and monitoring of internal and external quality related processes. It explicitly covers all processes that are outsourced to contract manufacturers, contract laboratories and other service providers, including all interfaces with suppliers, contractors and customers. |
| − | Depending on the size of the company and the number of branches and | + | Depending on the size of the company and the number of branches and subsidiaries, the PQS may apply to a single operation or to the whole group. Hybrid forms are also common in conglomerates: group-wide policies govern the corporate principles of the quality system and are supplemented by local documents for individual sites. These translate the global requirements of the company into local instructions. |
| − | The main regulatory requirements relevant to PQS can be found in Chapter 1 of the EU GMP Guide (RegLink EU-GMP Chapter 1). The requirements in | + | |
| + | The main regulatory requirements relevant to PQS can be found in Chapter 1 of the EU GMP Guide (RegLink EU-GMP Chapter 1). The requirements in Chapter 1 of the guidelines are supplemented by ICH Q10 (Pharmaceutical Quality System, RegLink ICH Q10 PQS). | ||
ICH Q10 has been incorporated into Part III of the EU GMP Guide and includes three important quality objectives: | ICH Q10 has been incorporated into Part III of the EU GMP Guide and includes three important quality objectives: | ||
| − | * Product Realisation: The PQS should enable the manufacture of | + | * Product Realisation: The PQS should enable the manufacture of products with quality attributes that meet the needs of patients, healthcare professionals and regulatory authorities. |
| − | * State of Control: The manufacturer should establish an effective | + | * State of Control: The manufacturer should establish an effective monitoring and control system: The manufacturer should establish effective monitoring and control systems to provide assurance of the continued suitability and capability of the processes. |
| − | * Continuous improvement: As "stagnation means regression", the | + | * Continuous improvement: As "stagnation means regression", the manufacturer is committed to identifying and implementing opportunities for improvement in the company's products, processes and systems using current sources of knowledge. |
* In order to achieve these objectives, the following elements of the PQS are central (see also Figure 1) | * In order to achieve these objectives, the following elements of the PQS are central (see also Figure 1) | ||
| − | * quality policy and planning (see | + | * quality policy and planning (see [[Quality policy, planning and objectives in the PQS|Quality policy, planning and objectives]]) |
| − | * documentation (see | + | * documentation (see ContLink 15 Documentation and Chapter 1.B The Documentation of the pharmaceutical quality system (PQS)) |
| − | * a wide range of tools (see | + | * a wide range of tools (see [[PQS tools|PQS Tools]]) |
| − | * suitable and adequate resources, i.e. premises, facilities, equipment and personnel (see | + | * suitable and adequate resources, i.e. premises, facilities, equipment and personnel (see ContLink 1.A.2 Resources). |
Figure 1: The PQS and its individual elements | Figure 1: The PQS and its individual elements | ||
| Zeile 40: | Zeile 41: | ||
[[Datei:The PQS and its individual elements.jpg|rahmenlos|links]] | [[Datei:The PQS and its individual elements.jpg|rahmenlos|links]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
== Links == | == Links == | ||
Aktuelle Version vom 19. Mai 2023, 19:22 Uhr
For companies manufacturing medicinal products, the terms quality management system (QMS) and pharmaceutical quality system (PQS) can be used interchangeably. As medicinal cannabis is classified as an active pharmaceutical ingredient (API) or medicinal product in the EU and is subject to EU GMP guidelines, the alternative usage also applies here. However, unlike a general ISO 900x QMS, a PQS must meet enhanced GMP requirements.
Tip! Use the term PQS consistently to avoid confusion with ISO quality man-agement systems used in other industries and often used by suppliers.
The documents, instructions and records of the PQS are used to control and verify the quality-related processes carried out during the production of medicinal cannabis, the active pharmaceutical ingredient (API) or the medicinal product, thus translating the relevant regulatory requirements into practical solutions.
Aims and basic principles of the PQS[Bearbeiten]
Any patient who is ill and takes a drug hopes that it will work and cure the disease or at least relieve the symptoms. However, the scandal in the USA in 1937 involving the preparation Elixir Sulfanilamide, which caused the deaths of 107 patients, and the Thalidomide disaster in Germany in the early 1960s made it clear that one thing is more important: medicinal products must be safe. Therefore, the primary objective of the pharmaceutical quality system (PQS) is patient safety. Chapter 1 of the EU GMP Guidelines (RegLink: Chapter 1, PQS) states that all holders of a Manufacturing Authorisation must ensure that the medicinal products manufactured are
- are fit for their intended use,
- comply with the requirements of the Marketing Authorisation or Clinical Trial Authorisation, and
- do not put patients at risk due to inadequate safety, quality or efficacy.
The last bullet point shows how important patient safety is to the authorities: safety always comes first, followed by the quality and efficacy of the medicinal product.
The fact that medicinal cannabis in its various forms of administration is classified as a medicinal product in Europe means that this also applies to the production and marketing of medicinal cannabis.
Several stakeholders with different roles are working together to achieve this goal: the growers and manufacturers of medicinal cannabis flowers and extracts, the wholesalers and the supervisory authorities.
If medicinal cannabis is used as an active ingredient in the manufacture of a medicine, the manufacturer of the medicine must apply for an EU marketing authorisation. This process is not covered by this knowledge portal.
Only products that meet the defined requirements can be placed on the market. The supervisory authorities carry out regular inspections of all manufac-urers of medicinal products to check their compliance with regulatory and pharmacopoeial requirements, including GMP and GDP. For this reason, European regulators also inspect the entire production chain of cannabis products worldwide.
The pharmaceutical manufacturer is obliged to implement, maintain and continuously improve a PQS (Pharmaceutical Quality System) to produce medicinal products that always meet the requirements. The PQS must be fully documented by means of instructions and records and must cover all aspects that individually or collectively affect the quality (and also safety and efficacy) of the medicinal product as specified in the pharmacopoeias. The PQS covers the entire lifecycle of the medicinal product from pharmaceutical development through technology transfer to commercial production until the product is discontinued. It also includes the development and monitoring of internal and external quality related processes. It explicitly covers all processes that are outsourced to contract manufacturers, contract laboratories and other service providers, including all interfaces with suppliers, contractors and customers.
Depending on the size of the company and the number of branches and subsidiaries, the PQS may apply to a single operation or to the whole group. Hybrid forms are also common in conglomerates: group-wide policies govern the corporate principles of the quality system and are supplemented by local documents for individual sites. These translate the global requirements of the company into local instructions.
The main regulatory requirements relevant to PQS can be found in Chapter 1 of the EU GMP Guide (RegLink EU-GMP Chapter 1). The requirements in Chapter 1 of the guidelines are supplemented by ICH Q10 (Pharmaceutical Quality System, RegLink ICH Q10 PQS).
ICH Q10 has been incorporated into Part III of the EU GMP Guide and includes three important quality objectives:
- Product Realisation: The PQS should enable the manufacture of products with quality attributes that meet the needs of patients, healthcare professionals and regulatory authorities.
- State of Control: The manufacturer should establish an effective monitoring and control system: The manufacturer should establish effective monitoring and control systems to provide assurance of the continued suitability and capability of the processes.
- Continuous improvement: As "stagnation means regression", the manufacturer is committed to identifying and implementing opportunities for improvement in the company's products, processes and systems using current sources of knowledge.
- In order to achieve these objectives, the following elements of the PQS are central (see also Figure 1)
- quality policy and planning (see Quality policy, planning and objectives)
- documentation (see ContLink 15 Documentation and Chapter 1.B The Documentation of the pharmaceutical quality system (PQS))
- a wide range of tools (see PQS Tools)
- suitable and adequate resources, i.e. premises, facilities, equipment and personnel (see ContLink 1.A.2 Resources).
Figure 1: The PQS and its individual elements
Links[Bearbeiten]
The importance of each of these elements to PQS is examined in detail in the articles